# Xinghua Dingli

> Xinghua Dingli is a VC fund backing Biotechnology and Medical. See 13 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 13
- Last investment: Aug 2026
- Lead investor: 46%
- Last updated: Aug 2026

Xinghua Dingli is an investment company.

## Contacts

5 contacts available for Xinghua Dingli. Shizune tracks 1 team members at Xinghua Dingli. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/xinghua-dingli?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.4M–$14M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 54% |
| Medical | 3 | 23% |
| Biopharma | 3 | 23% |
| Health Care | 3 | 23% |
| Pharmaceutical | 3 | 23% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 38% |
| Series A | 3 | 23% |
| Series B | 2 | 15% |
| Venture - Series Unknown | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| He Jiongling | Investment Director | 1 | https://shizune.co/investors/profile/he-jiongling |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Kaiwang Data | Kaiwang Data is a one-stop shop for data solutions. It focuses on offering complete data labeling solutions for automakers and businesses involved in autonomous driving. | $14.8M | Venture - Series Unknown | Aug 04, 2026 |  |
| Puyuan Bio | Primobiology is a developer of live microbial drugs for immune diseases. |  | Seed | May 30, 2024 |  |
| Puyuan Bio | Puyuan Bio engages in the clinical quantitative detection of tumor-specific mRNA in human peripheral blood. Its technology can provide an important clinical diagnosis basis for the presence of hematogenous spread of tumor cells and dynamic monitoring of the disease.The company has a talented team with doctoral tutors, doctors, and masters as themain body, and has 9 national invention patents in related fields. The company was approved by the Ministry of Science and Technology of Science and Technology Small and Medium Enterprises Technology Innovation Fund and passed the acceptance inspection. It is an enterprise settled in the technology transfer plan of Anhui Province and has been included in the Hefei Shuangqian Project. It was supported by the Development and Reform Commission in 2018.The registration application materials of the cytokeratin 19 (CK19) mRNA nucleic acid detection kit (PCR-fluorescent probe method) have been accepted by the State Food and Drug Administration, the on-site inspection of the medical device production quality management standard has been passed, and the approval number will be obtained soon. When it is put into production, it will contribute to public health. | $1.4M | Seed | May 30, 2024 |  |
| Inkedi Microelectronics | Inkodi Electronics is a manufacturer of electronic components that specializes in integrated circuit design, chip R&D and design, analog circuit layout design, and electronic component retail. | $14.1M | Seed | Dec 28, 2023 |  |
| Hydrogen Aviation Technology | Hydrogen Aviation Technology is committed to innovative applications of lightweight hydrogen fuel stacks. Its self-developed hydrogen-powered UAV has reached the international leading level. |  | Series A | Nov 07, 2023 |  |
| Tianji Jishi | Tianji Jishi is a biopharmaceutical company that specializes in researching mitochondria. |  | Series A | Oct 08, 2023 |  |
| Blue Aspirations | Blue Aspirations was formed to use statistics to accelerate the global adoption of renewable energy. Blue Aspirations aims to face the challenges of the next century by leveraging software development and technical knowledge in the renewables business. |  | Series B | Sep 22, 2023 |  |
| Hangzhou Weiyuan Biotechnology | Hangzhou Weiyuan Biotechnology is a synthetic biology research and development company that specializes in enzyme advancement. |  | Seed | Jun 30, 2023 |  |
| Nuoyu Pharmaceutical | Nuoyu Pharmaceutical is a medical innovative drug producer that emphasizes in nuclear drug research and drug screening. |  | Series A | May 13, 2023 |  |
| Puyuan Bio | Primobiology is a developer of live microbial drugs for immune diseases. | $1.5M | Seed | Jan 19, 2023 |  |

10 of 13 investments shown.

## Co-investors
- [Beijing Huafang Investment](https://shizune.co/investors/profile/beijing-huafang-investment) — VC Fund, 2 deals together
- [West Lake Science and Technology Direct Investment Fund](https://shizune.co/investors/profile/west-lake-science-and-technology-direct-investment-fund) — VC Fund, 2 deals together
- [Asia Capital Investment](https://shizune.co/investors/profile/asia-capital-investment) — VC Fund, 1 deal together
- [Conswall Capital](https://shizune.co/investors/profile/conswall-capital) — VC Fund, 1 deal together
- [Dongfang Jiafu](https://shizune.co/investors/profile/dongfang-jiafu) — VC Fund, 1 deal together
- [FutureX Capital](https://shizune.co/investors/profile/futurex-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Life Science Investors in China](https://shizune.co/investors/life-science-investors-china)
- [Life Science VC Funds in China](https://shizune.co/investors/life-science-vc-funds-china)

## FAQ

### What does Xinghua Dingli invest in?

Xinghua Dingli invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Xinghua Dingli's check size?

Xinghua Dingli typically joins rounds of $1.4M–$14M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Xinghua Dingli participates in.

### How do I contact Xinghua Dingli?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Xinghua Dingli?

The team at Xinghua Dingli includes He Jiongling (Investment Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co